Construction of an integrated diagnostic-therapeutic model for prostate cancer using rapid multiplex immunohistochemistry.
Adding rapid multiplex immunohistochemistry to frozen section raised prostate cancer detection sensitivity to 100%.
Construction of an integrated diagnostic-therapeutic model for prostate cancer using rapid multiplex immunohistochemistry.
To explore the feasibility and clinical application value of constructing an integrated model for the diagnosis and treatment of prostate cancer based on rapid multiplex immunohistochemistry (rapid multiplex immunohistochemistry) combined with intraoperative frozen section examination (intraoperative frozen section examination).
A total of 50 patients with high suspicion of localized prostate cancer were prospectively enrolled at our hospital between January and November 2025.
The overall pathological positivity rate in this study was 86.00% (43/50).
The concordance rate of Gleason score with postoperative pathology was 81.08%.
The Gleason score concordance rate improved to 97.44%.
The false-negative rate was 5.13% for intraoperative frozen section examination alone, compared to 0% for the combined intraoperative frozen section examination and rapid multiplex immunohistochemistry approach.
Rapid multiplex immunohistochemistry effectively compensates for the limitations of intraoperative frozen section examination alone.
The combined application of intraoperative frozen section examination and rapid multiplex immunohistochemistry within an integrated diagnostic–therapeutic model for prostate cancer significantly improves intraoperative diagnostic sensitivity and Gleason score accuracy without substantially extending waiting time.